Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis

A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis

The objective of this study is to assess the efficacy and safety of gevokizumab in treating Behcet's disease uveitis (BDU).

Inclusion Criteria:

• Have characteristics of Behcet's disease consistent with International Criteria for Behcet's disease
• Have a documented history of active uveitis with or without retinal vasculitis within the past 12 months
• Best corrected visual acuity (BCVA) >= 20 ETDRS letters in both eyes at baseline
• Effective contraceptive measures

Exclusion Criteria:

• Infectious uveitis and masquerade syndromes
• End stage ocular disease
• History of allergic or anaphylactic reactions to monoclonal antibodies
• Active tuberculosis disease
• History of recurrent infection or predisposition to infection; active ocular infection
• Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply